MacroGenics, Inc. (MGNX) Stock
Key stats
- Market cap
- $147.78M
- Price / Earnings ratio
- -10.6x
- EPS (TTM)
- -$0.22
- Volume
- Loading
- 52-week high
- $5.08
- 52-week low
- $1.32
Source: third-party data provider, as of November 13, 2026
Compare with MGNX
Recent news

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
MGNX

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
MGNX

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MGNX

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
MGNX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 34.47
- MACD 12/26/9
- -0.33
- EMA 9 of MACD
- -0.35
- MACD histogram
- 0.02
- SMA 50
- $3.41
- Price below SMA 50
- EMA 50
- $3.17
- Price below EMA 50
- SMA 200
- $3.44
- Price below SMA 200
- EMA 200
- $3.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
MGNX

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
MGNX

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MGNX

MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
MGNX

MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
MGNX

Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
MGNX

MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside
MGNX Stock Hits 16-Month High, But This Analyst Sees Another 140% Potential Upside
MGNX

MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies
MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies
MGNX

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates
MGNX

4 Medical Product Stocks to Watch From a Challenging Industry
4 Medical Product Stocks to Watch From a Challenging Industry
MGNX
News tone: automated (AI) classification of the article's content, not a price prediction.
About MacroGenics, Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Eric Blasius Risser | CEO, President & Director | 1973 |
| Mr. James Karrels | Senior VP & CFO | 1967 |
| Dr. Ezio Bonvini M.D. | Senior VP of Research & Chief Scientific Officer | 1954 |
| Dr. Araba Lamouse-Smith Ph.D. | Vice President of Technical Operations | — |
| Mr. Jeffrey Stuart Peters J.D. | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer | 1971 |
| Mr. Steve Harig | Senior Vice President of Human Resources | — |
| Mr. Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning | — |
| Dr. Frank George Perabo FEBU, M.D., Ph.D. | Vice President & Interim Head of Clinical Development | 1964 |
| Ms. Beth Smith | VP, Controller & Treasurer | 1968 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 34.47
- MACD 12/26/9
- -0.33
- EMA 9 of MACD
- -0.35
- MACD histogram
- 0.02
- SMA 50
- $3.41
- Price below SMA 50
- EMA 50
- $3.17
- Price below EMA 50
- SMA 200
- $3.44
- Price below SMA 200
- EMA 200
- $3.11
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $11.00
- Average
- $11.00
- High
- $11.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.9 | -3.4 | ||||||||||
| 2022 | -26.9 | -21.8 | -4.4 | -25.1 | -54.3 | -11.7 | +2.6 | +27.2 | -15.8 | +46.3 | +24.1 | -3.0 |
| 2023 | -9.3 | +2.4 | +15.1 | -8.6 | -37.0 | +15.8 | -11.3 | -4.5 | -4.1 | +16.5 | +55.2 | +14.8 |
| 2024 | +40.5 | +17.5 | -22.8 | +5.4 | -73.7 | -5.1 | +9.3 | |||||
| 2026 | +0.0 | +49.0 | +6.2 | +32.9 | +11.6 | -20.1 | +4.5 | -4.5 | -33.3 | -0.4 |



